How common are fibromyalgia and CFS in the UK? 

Fibromyalgia and chronic fatigue syndrome (CFS), often referred to as ME/CFS, are among the most frequently diagnosed long-term health conditions in the United Kingdom. Both conditions are characterised by persistent exhaustion and widespread pain, significantly impacting the physical and mental well-being of those affected. In recent years, the number of people reported to be living with these illnesses has risen, partly due to increased clinical awareness and the emergence of post-viral conditions. Understanding the prevalence of these conditions is vital for ensuring that the NHS can provide adequate support and that patients feel validated in their medical journeys. 

What We’ll Discuss in This Article 

• Current estimates for the number of people living with fibromyalgia 

• The rising prevalence of ME/CFS according to the latest UK data 

• How gender and age influence the likelihood of a diagnosis 

• The impact of post-viral fatigue and Long Covid on national statistics 

• Regional variations and the “diagnostic lottery” in the UK 

• The economic and social burden of these chronic conditions 

The prevalence of fibromyalgia in the UK population 

Fibromyalgia is one of the most common chronic pain conditions in the UK, affecting a significant percentage of the adult population. According to data cited in recent medical reviews, the prevalence of fibromyalgia is estimated to be between 2% and 5.4% of the general population. This translates to roughly 1.7 million to 2.8 million people living with the condition across the four nations. The variation in these figures often depends on the diagnostic criteria used by clinicians, as the condition is notoriously difficult to identify in its early stages. 

The condition is much more common than many people realise, yet it remains under-diagnosed in certain demographics. Studies published in the UK indicate that it often takes an average of over two years for a patient to receive a formal diagnosis after they first seek medical help. This delay is frequently due to the overlap of symptoms with other musculoskeletal disorders. According to the NHS, fibromyalgia can affect anyone, but it is most frequently diagnosed in people between the ages of 30 and 50. The high prevalence rates suggest that in a typical GP practice, a significant number of patients will be managing some form of chronic widespread pain related to this syndrome. 

The impact of fibromyalgia on the UK healthcare system is substantial. It is one of the leading causes of referrals to rheumatology clinics and pain management services. Because there is no single biological marker or blood test to confirm the condition, the diagnosis relies heavily on clinical history and the exclusion of other diseases. This complexity means that the reported statistics may still be lower than the actual number of people suffering, as many individuals may manage their symptoms without ever receiving a formal medical label. 

Understanding the statistics for ME/CFS 

Myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS) has historically been estimated to affect around 250,000 people in the United Kingdom. However, recent research and updated clinical reports suggest that this figure was likely a significant underestimation. New data from 2024 and 2025, which analysed over 60 million NHS health records, indicates that the number of people living with a confirmed diagnosis of ME/CFS is closer to 404,000. This represents approximately 0.6% of the UK population, a figure that highlights the widespread nature of this debilitating illness. 

The increase in recorded cases is attributed to several factors, including better adherence to the NICE guidelines for ME/CFS diagnosis which were updated in 2021. These guidelines encourage earlier identification of the four core symptoms: debilitating fatigue, post-exertional malaise, unrefreshing sleep, and cognitive difficulties. As GPs become more familiar with these criteria, more patients are being correctly identified and entered into the national health statistics. This trend is expected to continue as medical education around the condition improves. 

Furthermore, the prevalence of ME/CFS is not uniform across all groups. Research suggests that for every 10,000 patients in a general practice, about 40 will have ME/CFS. Of these individuals, approximately 25% are estimated to be severely or very severely affected, often meaning they are housebound or bedbound. These figures underscore the fact that ME/CFS is not just a condition of “feeling tired,” but a serious medical issue that places a heavy burden on both the individuals affected and their carers. 

Gender and age distributions in chronic conditions 

A striking feature of both fibromyalgia and ME/CFS in the UK is the disproportionate impact on women. Clinical data consistently show that women are significantly more likely to be diagnosed with these conditions than men. In the case of fibromyalgia, some statistics suggest that women make up over 90% of hospital admissions related to the syndrome. For ME/CFS, the ratio is slightly less extreme but still significant, with women being roughly three to four times more likely to be affected than their male counterparts. 

The reasons for this gender disparity are still being studied by UK researchers. Some theories suggest that hormonal differences or variations in the way the immune system responds to stress and infection may play a role. There is also a suggestion that social factors, such as women being more likely to report persistent pain to their GP, could influence the recorded statistics. However, most experts agree that the biological basis for the higher prevalence in females is a primary factor. 

Age also plays a critical role in the prevalence data. While these conditions can affect children and young people, they are most commonly diagnosed in middle age. Fibromyalgia prevalence tends to peak between the ages of 40 and 60. For ME/CFS, the peak age for diagnosis is often in the 40s or 50s, though there is a secondary peak often seen in teenagers and young adults. As the UK population ages, the number of people living with these long-term conditions is expected to grow, placing further demand on primary care services. 

The impact of Long Covid on national figures 

The landscape of chronic fatigue in the UK has changed dramatically since 2020. The emergence of Long Covid has added a new dimension to the prevalence of fatigue-based illnesses. Many of the symptoms of Long Covid, such as extreme exhaustion, brain fog, and post-exertional malaise, overlap significantly with the diagnostic criteria for ME/CFS. Recent reports from the Office for National Statistics (ONS) suggest that over 2 million people in the UK have reported symptoms of Long Covid lasting more than four weeks. 

Healthcare experts now estimate that a substantial portion of those with Long Covid may meet the clinical criteria for a diagnosis of ME/CFS. Some projections suggest that the number of people in the UK living with ME/CFS-like symptoms could rise as high as 1.35 million if the current trends in post-viral recovery continue. This potential tripling of the patient population represents a major challenge for the NHS and suggests that the historic figure of 250,000 is no longer an accurate reflection of the current health crisis. 

This influx of new patients has led to increased government focus on the condition. The UK government’s final delivery plan for ME/CFS, published in 2025, acknowledges that the prevalence of these conditions is a significant public health issue. The plan emphasises the need for better training for healthcare professionals to ensure that those suffering from post-viral fatigue receive timely and accurate assessments. The surge in cases has also driven new research into the biological mechanisms of fatigue, which may eventually benefit patients with both Long Covid and traditional ME/CFS. 

Regional variations and the “diagnostic lottery” 

One of the most concerning aspects of the prevalence data in the UK is the geographic variation in diagnosis rates. Research from the University of Edinburgh in 2025 highlighted what has been described as a “diagnostic lottery.” The study found that the likelihood of receiving a diagnosis for ME/CFS or fibromyalgia depends heavily on where a person lives in the UK. Some regions have recorded prevalence rates ten times higher than others, even when accounting for population size. 

For instance, certain areas in the south-west of England, such as Cornwall, have reported some of the highest rates of diagnosis in the country. Conversely, some urban areas in London and the north of England have significantly lower recorded numbers. These discrepancies are often linked to the availability of specialist clinics and the level of awareness among local GPs. In some deprived areas, there are hundreds of GP practices with no recorded cases of ME/CFS at all, which researchers suggest is a sign of under-diagnosis rather than an absence of the condition. 

Ethnicity also appears to influence the statistics. The same studies found that people from Asian, Black, and other minority ethnic backgrounds are substantially less likely to be diagnosed with ME/CFS than White British people. This suggests that barriers to healthcare and potential biases in clinical assessment may be skewing the national data. Addressing these inequalities is a priority for the NHS to ensure that prevalence statistics accurately reflect the health of the entire UK population. 

The economic and social cost of chronic illness 

The high prevalence of fibromyalgia and ME/CFS has a profound impact on the UK economy. Because these conditions often affect people during their prime working years, they result in a significant loss of productivity. Estimates suggest that the annual cost of chronic pain to the UK economy exceeds £100 billion, driven by millions of lost workdays and the costs of healthcare and social benefits. For an individual, the lifetime cost of living with a severe chronic pain condition can be immense, often leading to reduced earning potential and financial instability. 

Beyond the financial cost, the social burden is equally heavy. Many people living with these conditions experience social isolation, as their symptoms make it difficult to maintain friendships and participate in community life. The mental health impact is also significant, with individuals suffering from chronic fatigue or pain being four times more likely to experience depression or anxiety. This secondary impact further increases the complexity of managing the conditions and places additional strain on mental health services. 

The prevalence data highlight the urgent need for a cohesive national strategy to manage these conditions. By recognising that millions of people are affected, the UK can move toward a system that provides more consistent care and better support for self-management. Investment in research is also crucial, as a better understanding of why these conditions are so common could lead to more effective treatments and, eventually, a reduction in the overall disease burden. 

Conclusion 

The latest statistics reveal that fibromyalgia and ME/CFS are remarkably common in the UK, affecting millions of people across all age groups and regions. With fibromyalgia affecting up to 5.4% of the population and ME/CFS cases rising toward 400,000, these conditions represent a major health priority for the NHS. While women remain the most affected demographic, the surge in post-viral cases following the pandemic has made these issues a mainstream public health concern. Ensuring equitable access to diagnosis and support is the next critical step for the UK healthcare system. 

If you experience severe, sudden, or worsening symptoms, call 999 immediately. 

Authority Snapshot (E-E-A-T Block) 

This article provides an evidence-based overview of the prevalence of fibromyalgia and chronic fatigue syndrome in the UK. It was written by the MyPatientAdvice team and reviewed by Dr. Stefan Petrov to ensure all statistics and clinical information align with the latest NHS and NICE guidance. The purpose of this content is to educate the public on the scale and impact of these long-term conditions within the British healthcare landscape.